BioVision

05/14

PRODUCT: AT 56

ALTERNATE NAME: 4-(5*H*-Dibenzo[*a*,*d*]cyclohepten-5-ylidene)-1-[4-(2*H*-tetrazol-5-yl)butyl]-piperidine

CATALOG #: 2592-5, 25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{25}H_{27}N_5$

MOLECULAR WEIGHT: 397.52

CAS No. 162640-98-4

APPEARANCE: White solid

SOLUBILITY: DMSO (>15 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20ºC. Protect from light and air

DESCRIPTION: AT-56 is a selective, competitive, and highly bioavailable inhibitor of L-PGDS (lipocalin-type prostaglandin D synthase) (K_i = 75 µM). It inhibits the production of PGD_2 by L-PGDS purified from human CSF and recombinant mouse cells with an IC_{50} value of 95 µM. At concentrations as high as 100 µM *in vitro* or 30 mg/kg *in vivo*, AT-56 does not affect the production of PGE_2, $PGF_{2\alpha}$, or H-PGDS-catalyzed PGD_2.

REFERENCES:

Irikura, D., *et al.* (2009). *J. Biol. Chem.* **284,** 7623-7630.

.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

AKR1C1, human recombinant **(Cat. No. 6336-100)**
AKR1C3, human recombinant **(Cat. No. 6337-100)**
AKR1C4, human recombinant **(Cat. No. 6338-100)**
AKR1C3 Inhibitor I **(Cat. No. 2403-5, 25)**
AKR1C3 Inhibitor II **(Cat. No. 2404-5, 25)**
AKR1C3 Inhibitor III **(Cat. No. 2424-5, 25**
Prostaglandin E2 **(Cat. No. 2268-5, 25)**

USAGE: ***FOR RESEARCH USE ONLY! Not to be used in humans.***

BioVision Incorporated
155 S. Milpitas Boulevard, Milpitas, CA 95035 USA

Tel: 408-493-1800 | Fax: 408-493-1801
www.biovision.com | tech@biovision.com